Media Summary: Lisa Carey, MD, ScM, FASCO, from the University of North Carolina, Chapel Hill, NC, outlines the pivotal Phase III trial Dr Aditya Bardia spoke to ecancer online about the the randomised phase 3 Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III ...
Ascent Sacituzumab Govitecan Outperforms Chemo - Detailed Analysis & Overview
Lisa Carey, MD, ScM, FASCO, from the University of North Carolina, Chapel Hill, NC, outlines the pivotal Phase III trial Dr Aditya Bardia spoke to ecancer online about the the randomised phase 3 Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the Phase III ... Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, describes the trial design and rationale of the Phase III ... Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the results from the Aditya Bardia reports on key results from ESMO Virtual Congress 2020 on LBA17:
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, outlines the updated biomarker analysis results of the ... Sara Hurvitz, MD, Ronald Reagan UCLA Medical Center, Los Angeles, CA, discusses the results of the Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors Dr Javier ... New hope for triple-negative breast cancer (TNBC)! The Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the final overall survival (OS) analysis of the Phase ... Dr Jane Meisel comments on Dr Hope Hugo's study on the use of
